Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

[1]  A. Tamhane,et al.  Multiple Comparison Procedures , 2009 .

[2]  W. Loging,et al.  Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. , 2009, Endocrinology.

[3]  Daniel Bloomfield,et al.  Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. , 2009, American heart journal.

[4]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[5]  J. Stockman,et al.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial , 2009 .

[6]  A. Capponi,et al.  Abstract 3618: No Increase in the In Vitro Production of Aldosterone or the Expression of CYP11B2 with the CETP Modulator Dalcetrapib (RO4607381/JTT-705), in Contrast with Torcetrapib , 2008 .

[7]  J. Ehrhart,et al.  Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone , 2008, British journal of pharmacology.

[8]  J. Kastelein,et al.  COMPARISON OF EFFECTS OF TORCETRAPIB AND RO4607381/JTT-705 ON BLOOD PRESSURE AND TISSUE EXPRESSION OF RENIN-ANGIOTENSIN SYSTEM-RELATED GENES IN RATS , 2008 .

[9]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[10]  W. Howard,et al.  Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis , 2008 .

[11]  John A Wagner,et al.  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.

[12]  D. Rader.  Illuminating HDL--is it still a viable therapeutic target? , 2007, The New England journal of medicine.

[13]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[14]  T. Mazzone.  HDL cholesterol and atherosclerosis , 2007, The Lancet.

[15]  A. Tall.  CETP inhibitors to increase HDL cholesterol levels. , 2007, The New England journal of medicine.

[16]  B. Wolffenbuttel,et al.  CETP inhibition in cardiovascular risk management: a critical appraisal , 2007, European journal of clinical investigation.

[17]  A. Tall,et al.  The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[18]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. , 2006, Journal of the American College of Cardiology.

[19]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. , 2006, Journal of the American College of Cardiology.

[20]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[21]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[22]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[23]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[24]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[25]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[26]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[27]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[28]  A. Gotto.  High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. , 2002, American heart journal.

[29]  Jan Nilsson,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.

[30]  S. Kaul,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.

[31]  Unstable angina pectoris. , 2000, The New England journal of medicine.

[32]  A. Tall.  Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.

[33]  J. G. Skellam.  A Probability Distribution Derived from the Binomial Distribution by Regarding the Probability of Success as Variable between the Sets of Trials , 1948 .